巴西准紧急使用科兴及阿斯利康疫苗 挪威吁末期重症患者勿接种疫苗
巴西向科兴(SVA.US)及阿斯利康(AZN.US)新冠病毒疫苗批出紧急使用授权,当局将於未来数日将600万剂科兴疫苗运到全国,预计周三可以展开大规模接种计划。
另外,挪威药品管理局修改接种指引,呼吁有末期病患长者不应接种疫苗,因有末期病患长者接种辉瑞(PFE.US)疫苗後出现副作用死亡,但强调对疫苗充满信心。
挪威已有逾3万人接种第一剂辉瑞或Moderna(MRNA.US)的疫苗,当中有33人出现副作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.